Anabolic abuse

How is testosterone therapy different from anabolic steroid abuse?

One reason testosterone therapy is surrounded by controversy is that testosterone can be abused, both in athletic populations and among the general public.1 Scientific evidence is undisputed that testosterone is extremely potent in increasing muscle growth and enhancing physical performance.1-3 The ethical issue of fair play in sports, coupled with the well-documented adverse health effects of supra-physiological doses of testosterone 4 or anabolic steroids 5-15, has given medically legitimate testosterone therapy a bad reputation. This is unfortunately depriving many men suffering from hypogonadism from receiving medically needed testosterone therapy.16

What follows is an overview of the salient differences between use of testosterone therapy that is medically legitimate, and abuse of testosterone and anabolic steroids (which are synthetic derivatives of testosterone), and explain why testosterone therapy - which per definition is medically provided and supervised - has no parallel with abuse of testosterone and anabolic steroids.

What are anabolic steroids?

In order to understand the differences between testosterone therapy and anabolic steroid use, it is important to know what anabolic steroids are.

Anabolic-androgenic steroids (AAS), popularly known as “anabolic steroids”, “anabolics” or “steroids”, include synthetic derivatives of testosterone, which were originally developed in the late 1930s.17-22 Testosterone in its unmodified form is also classified as an anabolic steroid, and listed among its synthetic derivatives as a banned substance by the World Anti-Doping Agency (WADA).23 Testosterone and anabolic steroids are legally classified as Schedule III controlled substances, and thus require a doctor’s prescription when used for medical purposes.

Are there any medical indications for use of anabolic steroids?

It may come as a surprise to most people that there are actually several medical indications for the use anabolic steroids 24,25; including sarcopenia and frailty 26-28, rehabilitation after hip fracture 29,30 and after knee arthroplasty 31-33, treatment of osteoporosis and prevention of fractures 30,34-46, wound healing 47,48, leukemia 49,50, treatment of muscle wasting 51,52 and anemia 53 in dialysis patients, as well as treatment of wasting seen in patients with chronic obstructive pulmonary disease 54 and HIV.55 Note that these benefits are seen in these clinical populations of both men and women.

The fact that testosterone is classified as an anabolic steroid stirs up heated debates about testosterone therapy. However, hypogonadism is a disease that requires medical treatment, as lack of testosterone therapy results in well documented metabolic deterioration and diseases, including obesity, metabolic syndrome, diabetes and heart disease.56

New FDA warning on abuse and dependence of testosterone

The war on testosterone continues. On October 25th, 2016 the FDA issued a class-wide labeling change for all prescription testosterone products, adding a warning about the abuse potential of testosterone products. This created media headlines touting that testosterone therapy is bad because it carries addiction risk.

As explained in “Is testosterone therapy a lifelong treatment?” testosterone therapy is in most cases a lifelong treatment. Not because men with hypogonadism who start testosterone therapy become “addicted” to it, but because it relieves bothersome symptoms caused by low testosterone levels and improves wellbeing, mood and quality of life (as well as objective health status).

Below is a list of several important differences between testosterone therapy and abuse of anabolic steroids, which highlight why they should not be confused.

Dosages

Testosterone therapy that is prescribed and monitored by a doctor has well-established safety. In contrast, abusers of anabolic steroids use many-fold higher dosages than the recommended clinical doses.13 Doses up to 30 times greater than physiologic replacement doses have been reported.57 This results in supra-physiological blood levels of testosterone, in the range of 3000 – 5000 ng/dL. Compare this to the high end of the healthy physiological testosterone range, which is approx. 1300 ng/dL (depending on the laboratory assay, this value may vary +/- 300).

Continuous vs. cycling use

Testosterone replacement therapy is in most cases a lifelong treatment aimed to replace hypogonadal testosterone levels associated with aging and aging-related morbidities. In contrast, users of anabolic steroids cycle their use of preparations. Use of anabolic steroids often occurs in repeated cycles of around 12 weeks, followed by periods of non-use (breaks).57-59

However, it is becoming more and more common for anabolic steroid users to use anabolic steroids continuously - known as “cruising” - and on top of that add periodic cycles of other anabolic agents and/or increasing dosages – known as “blasting”.

Risks vs. benefits

The side effects of anabolic steroid use in high doses are well established in medical research.8,9,12,15,60-62 In contrast, long-term testosterone treatment is well-documented to be safe, and confers multiple health benefits.56,63,64  For more information on safety and benefits of testosterone therapy, see our Research News section, and the following reports:

Multiple beneficial effects of testosterone replacement therapy in men with testosterone deficiency

Testosterone deficiency and treatment - international expert consensus resolutions

UK policy statements on testosterone deficiency

Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease: real-life results

Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes

Incidence of prostate cancer after testosterone therapy for up to 17 years

Normalization of testosterone level is associated with reduced incidence of heart attack, stroke and mortality in men

Testosterone therapy and cardiovascular risk - advances and controversies

Stacking: multi-drug combinations

Abusers of testosterone frequently practice ‘‘stacking’’ – i.e. simultaneously use of testosterone combined with multiple synthetic derivatives of testosterone, a practice called polypharmacy.58,65-68 In addition to testosterone and synthetic derivatives of testosterone, high doses of growth hormone and insulin are also commonly added to the mix 67,69,  which further increased the health risks.

While polypharmacy may have synergistic effects on muscle growth and physical performance, it also results in more dangerous and potentially lethal consequences.60,70 In contrast, testosterone therapy in men with hypogonadism is done with testosterone (although for men who wish to become fathers in the near future, clomiphene citrate, hCG or aromatase inhibitors are recommended), which is provided in a controlled medical setting in physiological doses that improve health status.

Personal characteristics of users

Abuse of testosterone and anabolic steroids is strongly associated with illicit drug use and substance dependence,66,68,71 and aggressive alcohol use.72 Statements that testosterone therapy – which per definition is medically provided, monitored by physicians and fills important medical needs - supposedly is bad because it carries addiction risk, are unfounded. There is no evidence for testosterone abuse in men who are medically treated with testosterone therapy.73

Bottom line

It is important to keep in mind that just because something can be abused does not mean it has no medically legitimate use. Anything can be abused, even food. When considering the tremendous health benefits of testosterone therapy in hypogonadal men, the controversial discussions about testosterone therapy are moot if put in perspective. For example, one may question how come tobacco and alcohol – two highly addictive and widely available substances of abuse with no medical indications whatsoever - are legal, despite their widespread harms in society?

Recommendations

Testosterone deficiency FAQs

Low testosterone - causes and risk factors

References

  1. Basaria S. Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab. 2010;95(4):1533-1543.
  2. West DW, Phillips SM. Anabolic processes in human skeletal muscle: restoring the identities of growth hormone and testosterone. The Physician and sportsmedicine. 2010;38(3):97-104.
  3. Fitch KD. Androgenic-anabolic steroids and the Olympic Games. Asian journal of andrology. 2008;10(3):384-390.
  4. Bhasin S, Woodhouse L, Casaburi R, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab. 2005;90(2):678-688.
  5. Angell P, Chester N, Green D, Somauroo J, Whyte G, George K. Anabolic steroids and cardiovascular risk. Sports Med. 2012;42(2):119-134.
  6. Angell PJ, Chester N, Green DJ, et al. Anabolic steroid use and longitudinal, radial, and circumferential cardiac motion. Med Sci Sports Exerc. 2012;44(4):583-590.
  7. Angell PJ, Chester N, Sculthorpe N, Whyte G, George K, Somauroo J. Performance enhancing drug abuse and cardiovascular risk in athletes: implications for the clinician. Br J Sports Med. 2012;46 Suppl 1:i78-84.
  8. Angell PJ, Ismail TF, Jabbour A, et al. Ventricular structure, function, and focal fibrosis in anabolic steroid users: a CMR study. Eur J Appl Physiol. 2014;114(5):921-928.
  9. Baggish AL, Weiner RB, Kanayama G, et al. Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circulation Heart failure. 2010;3(4):472-476.
  10. Deligiannis AP, Kouidi EI. Cardiovascular adverse effects of doping in sports. Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese. 2012;53(6):447-457.
  11. Garevik N, Strahm E, Garle M, et al. Long term perturbation of endocrine parameters and cholesterol metabolism after discontinued abuse of anabolic androgenic steroids. J Steroid Biochem Mol Biol. 2011;127(3-5):295-300.
  12. Pope HG, Jr., Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341-375.
  13. Kersey RD, Elliot DL, Goldberg L, et al. National Athletic Trainers' Association position statement: anabolic-androgenic steroids. Journal of athletic training. 2012;47(5):567-588.
  14. Hoffman JR, Kraemer WJ, Bhasin S, et al. Position stand on androgen and human growth hormone use. J Strength Cond Res. 2009;23(5 Suppl):S1-S59.
  15. Achar S, Rostamian A, Narayan SM. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol. 2010;106(6):893-901.
  16. Morales A. The long and tortuous history of the discovery of testosterone and its clinical application. The journal of sexual medicine. 2013;10(4):1178-1183.
  17. Hoberman JM, Yesalis CE. The history of synthetic testosterone. Sci Am. 1995;272(2):76-81.
  18. Dotson JL, Brown RT. The history of the development of anabolic-androgenic steroids. Pediatr Clin North Am. 2007;54(4):761-769, xi.
  19. Kochakian CD. The evolution from "the male hormone" to anabolic- androgenic steroids. Ala J Med Sci. 1988;25(1):96-102.
  20. Joseph JF, Parr MK. Synthetic androgens as designer supplements. Current neuropharmacology. 2015;13(1):89-100.
  21. Wu C, Kovac JR. Novel Uses for the Anabolic Androgenic Steroids Nandrolone and Oxandrolone in the Management of Male Health. Current urology reports. 2016;17(10):72.
  22. Pan MM, Kovac JR. Beyond testosterone cypionate: evidence behind the use of nandrolone in male health and wellness. Transl Androl Urol. 2016;5(2):213-219.
  23. WADA. The World Anti-Doping Code. 2015.
  24. Basaria S, Wahlstrom JT, Dobs AS. Clinical review 138: Anabolic-androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab. 2001;86(11):5108-5117.
  25. Taylor WN. Anabolic Therapy in Modern Medicine McFarland; 2002.
  26. Morley JE. Anabolic steroids and frailty. Journal of the American Medical Directors Association. 2010;11(8):533-536.
  27. Bhasin S. The brave new world of function-promoting anabolic therapies: testosterone and frailty. J Clin Endocrinol Metab. 2010;95(2):509-511.
  28. Bross R, Javanbakht M, Bhasin S. Anabolic interventions for aging-associated sarcopenia. J Clin Endocrinol Metab. 1999;84(10):3420-3430.
  29. Farooqi V, van den Berg ME, Cameron ID, Crotty M. Anabolic steroids for rehabilitation after hip fracture in older people. Cochrane Database Syst Rev. 2014;10:CD008887.
  30. Hedstrom M, Sjoberg K, Brosjo E, Astrom K, Sjoberg H, Dalen N. Positive effects of anabolic steroids, vitamin D and calcium on muscle mass, bone mineral density and clinical function after a hip fracture. A randomised study of 63 women. J Bone Joint Surg Br. 2002;84(4):497-503.
  31. Hohmann E, Tetsworth K, Hohmann S, Bryant AL. Anabolic steroids after total knee arthroplasty. A double blinded prospective pilot study. Journal of orthopaedic surgery and research. 2010;5:93.
  32. Wu BW, Berger M, Sum JC, Hatch GF, 3rd, Schroeder ET. Randomized control trial to evaluate the effects of acute testosterone administration in men on muscle mass, strength, and physical function following ACL reconstructive surgery: rationale, design, methods. BMC surgery. 2014;14:102.
  33. Metcalfe D, Watts E, Masters JP, Smith N. Anabolic steroids in patients undergoing total knee arthroplasty. BMJ open. 2012;2(5).
  34. Frisoli A, Jr., Chaves PH, Pinheiro MM, Szejnfeld VL. The effect of nandrolone decanoate on bone mineral density, muscle mass, and hemoglobin levels in elderly women with osteoporosis: a double-blind, randomized, placebo-controlled clinical trial. J Gerontol A Biol Sci Med Sci. 2005;60(5):648-653.
  35. Need AG, Durbridge TC, Nordin BE. Anabolic steroids in postmenopausal osteoporosis. Wien Med Wochenschr. 1993;143(14-15):392-395.
  36. Geusens P. Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis. Clin Rheumatol. 1995;14 Suppl 3:32-39.
  37. Geusens P, Dequeker J. Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Bone Miner. 1986;1(4):347-357.
  38. Hamdy RC, Moore SW, Whalen KE, Landy C. Nandrolone decanoate for men with osteoporosis. Am J Ther. 1998;5(2):89-95.
  39. Vanderschueren D, Laurent MR, Claessens F, et al. Sex steroid actions in male bone. Endocr Rev. 2014:er20141024.
  40. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84(6):1966-1972.
  41. Meriggiola MC, Armillotta F, Costantino A, et al. Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals. The journal of sexual medicine. 2008;5(10):2442-2453.
  42. Kenny AM, Kleppinger A, Annis K, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc. 2010;58(6):1134-1143.
  43. Clarke BL, Khosla S. Androgens and bone. Steroids. 2009;74(3):296-305.
  44. Basurto L, Zarate A, Gomez R, Vargas C, Saucedo R, Galvan R. Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men. The aging male : the official journal of the International Society for the Study of the Aging Male. 2008;11(3):140-145.
  45. Anderson FH, Francis RM, Faulkner K. Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone. 1996;18(2):171-177.
  46. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004;89(2):503-510.
  47. Demling R, De Santi L. Closure of the "non-healing wound" corresponds with correction of weight loss using the anabolic agent oxandrolone. Ostomy Wound Manage. 1998;44(10):58-62, 64, 66 passim.
  48. Demling RH, Orgill DP. The anticatabolic and wound healing effects of the testosterone analog oxandrolone after severe burn injury. J Crit Care. 2000;15(1):12-17.
  49. Sotto JJ, Hollard D, Schaerer R, Bensa JC, Seigneurin D. [Androgens and prolonged complete remissions in acute non lymphoblastic leukemias. Results of a systematic treatment with stanozolol associated with chemotherapy (author's transl)]. Nouv Rev Fr Hematol. 1975;15(1):57-72.
  50. Hollard D, Sotto JJ, Bachelot C, et al. [Trial of androgen therapy in the treatment of non-lymphoblastic acute leukemia. First results]. Nouv Presse Med. 1976;5(20):1289-1293.
  51. Chen CT, Lin SH, Chen JS, Hsu YJ. Muscle wasting in hemodialysis patients: new therapeutic strategies for resolving an old problem. TheScientificWorldJournal. 2013;2013:643954.
  52. Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA. 1999;281(14):1275-1281.
  53. Paul AK, Latif ZA, Iqbal S, Amin F, Shefin SM, Ashrafuzzaman SM. Androgen versus erythropoietin for the treatment of anaemia of pre-dialysis chronic kidney disease. Mymensingh medical journal : MMJ. 2012;21(1):125-128.
  54. Pan L, Wang M, Xie X, Du C, Guo Y. Effects of anabolic steroids on chronic obstructive pulmonary disease: a meta-analysis of randomised controlled trials. PloS one. 2014;9(1):e84855.
  55. Saha B, Rajadhyaksha GC, Ray SK. Beneficial effects of nandrolone decanoate in wasting associated with HIV. J Indian Med Assoc. 2009;107(5):295-299.
  56. Morgentaler A, Zitzmann M, Traish AM, et al. Fundamental Concepts Regarding Testosterone Deficiency and Treatment: International Expert Consensus Resolutions. Mayo Clin Proc. 2016;91(7):881-896.
  57. Perry PJ, Lund BC, Deninger MJ, Kutscher EC, Schneider J. Anabolic steroid use in weightlifters and bodybuilders: an internet survey of drug utilization. Clin J Sport Med. 2005;15(5):326-330.
  58. McCabe SE, Brower KJ, West BT, Nelson TF, Wechsler H. Trends in non-medical use of anabolic steroids by U.S. college students: results from four national surveys. Drug Alcohol Depend. 2007;90(2-3):243-251.
  59. Kersey RD. Anabolic-androgenic steroid use among california community college student-athletes. Journal of athletic training. 1996;31(3):237-241.
  60. Frati P, Busardo FP, Cipolloni L, Dominicis ED, Fineschi V. Anabolic Androgenic Steroid (AAS) related deaths: autoptic, histopathological and toxicological findings. Current neuropharmacology. 2015;13(1):146-159.
  61. Nieminen MS, Ramo MP, Viitasalo M, et al. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur Heart J. 1996;17(10):1576-1583.
  62. Payne JR, Kotwinski PJ, Montgomery HE. Cardiac effects of anabolic steroids. Heart. 2004;90(5):473-475.
  63. Haider A, Zitzmann M, Doros G, Isbarn H, Hammerer P, Yassin A. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries. J Urol. 2015;193(1):80-86.
  64. Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone Therapy and Cardiovascular Risk: Advances and Controversies. Mayo Clin Proc. 2014.
  65. Turillazzi E, Perilli G, Di Paolo M, Neri M, Riezzo I, Fineschi V. Side effects of AAS abuse: an overview. Mini reviews in medicinal chemistry. 2011;11(5):374-389.
  66. Ip EJ, Barnett MJ, Tenerowicz MJ, Perry PJ. The Anabolic 500 survey: characteristics of male users versus nonusers of anabolic-androgenic steroids for strength training. Pharmacotherapy. 2011;31(8):757-766.
  67. Baker JS, Graham MR, Davies B. Steroid and prescription medicine abuse in the health and fitness community: A regional study. European journal of internal medicine. 2006;17(7):479-484.
  68. Sagoe D, McVeigh J, Bjornebekk A, Essilfie MS, Andreassen CS, Pallesen S. Polypharmacy among anabolic-androgenic steroid users: a descriptive metasynthesis. Substance abuse treatment, prevention, and policy. 2015;10:12.
  69. Albertson TE, Chenoweth JA, Colby DK, Sutter ME. The Changing Drug Culture: Use and Misuse of Appearance- and Performance-Enhancing Drugs. FP Essent. 2016;441:30-43.
  70. Pomara C, Neri M, Bello S, Fiore C, Riezzo I, Turillazzi E. Neurotoxicity by synthetic androgen steroids: oxidative stress, apoptosis, and neuropathology: A review. Current neuropharmacology. 2015;13(1):132-145.
  71. Hakansson A, Mickelsson K, Wallin C, Berglund M. Anabolic androgenic steroids in the general population: user characteristics and associations with substance use. Eur Addict Res. 2012;18(2):83-90.
  72. Ip EJ, Trinh K, Tenerowicz MJ, Pal J, Lindfelt TA, Perry PJ. Characteristics and Behaviors of Older Male Anabolic Steroid Users. Journal of pharmacy practice. 2015;28(5):450-456.
  73. Brower KJ. Anabolic steroid abuse and dependence. Current psychiatry reports. 2002;4(5):377-387.
  • PP-NEB-ALL-0344-2

Copyright © 2019,
Bayer AG

This website is intended to provide information to an international audience outside the USA and UK.

Page last modified Tue, 15/10/2019

Bayer logo